Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Improvements in screening, diagnosis and treatment of cancer has seen cancer mortality
substantially diminish in the past three decades. It is estimated there are almost 20 million …

Peripheral neurologic complications are frequent adverse events during oncologic
treatments and often lead to dose reduction, administration delays with time elongation of …

The rates of ribosome production by a nucleolus and of protein biosynthesis by ribosomes
are tightly correlated with the rate of cell growth and proliferation. All these processes must …

Oxaliplatin‐induced peripheral neuropathy (OIPN) is a common and dose‐limiting toxic
effect that markedly limits the use of oxaliplatin and affects the quality of life. Although it is …

Oxaliplatin-induced neurotoxicity is expressed as a dose-limiting peripheral sensory
neuropathy (PSN). Cannabinoid substances have been investigated for the analgesic effect …

Background: Painful peripheral neuropathy is a dose-limiting adverse effect of the antitumor
drug oxaliplatin. The main symptoms of neuropathy: tactile allodynia and cold hyperalgesia …

Oxaliplatin is a third-generation platinum drug commonly used as the first line treatment of
metastatic colorectal cancer. Oxaliplatin-based anticancer regimens course with dose …

Abstract Background and Aims Cisplatin (CDDP) is used as the first line of treatment for
some tumors, but its use may be restricted due to its nephrotoxicity. Carboplatin (CARBO) …